← All trials
NCT04627025
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 26, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Nov 13, 2020
- Last posted
- Nov 24, 2021
- Enrollment
- 144
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- VectivBio AGLead sponsor
- VectivBio AGStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.